# Bristol-Myers Squibb (BMY) — Earnings

BMY · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/bmy/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $2.04 |
| EPS estimate | $1.60 |
| EPS surprise | +27.73% |
| Revenue surprise | +10.51% |
| Revenue | $13.0B |
| Revenue estimate | $11.7B |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a5f09764-e18f-0fb1-e229-a4f150a155a3.html) |

Bristol-Myers Squibb reported Q2 2026 results on July 30, 2026. Earnings per share came in at $2.04, ahead of the $1.60 estimate by 27.73%. Revenue was $13.0 billion, 10.51% above the $11.7 billion consensus. Compared with Q2 2025, EPS rose about 40% from $1.46 and revenue rose about 6% from $12.3 billion.

The longer record is shaped by one loss quarter. In Q1 2024, the company posted a loss of $4.40 per share, close to the expected loss of $4.41. That pulled annual EPS for 2024 down to $1.14, against $7.70 in 2022, $7.50 in 2023 and $6.15 in 2025. Revenue has been far steadier, at $45.0 billion to $48.3 billion a year. The first half of 2026 adds up to $3.62 per share, about 11% more than a year earlier. Q2 2026 set the revenue high in the table, while the EPS high was $2.07 in Q2 2024. Over the last 20 quarters, Bristol-Myers Squibb topped the EPS estimate 19 times. The only miss was Q2 2023, at 10.79% below.

The company reported Q3 between October 26 and October 31 in each of the past five years. That points to late October 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $1.60 | $2.04 | 27.73% | $11.7B | $13.0B |
| Q1 2026 | Apr 30, 2026 | $1.42 | $1.58 | 10.99% | $10.9B | $11.5B |
| Q4 2025 | Feb 5, 2026 | $1.23 | $1.26 | 2.79% | $12.3B | $12.5B |
| Q3 2025 | Oct 30, 2025 | $1.52 | $1.63 | 7.41% | $11.9B | $12.2B |
| Q2 2025 | Jul 31, 2025 | $1.09 | $1.46 | 33.79% | $11.4B | $12.3B |
| Q1 2025 | Apr 24, 2025 | $1.49 | $1.80 | 20.43% | $10.7B | $11.2B |
| Q4 2024 | Feb 6, 2025 | $1.46 | $1.67 | 14.13% | $11.6B | $12.3B |
| Q3 2024 | Oct 31, 2024 | $1.49 | $1.80 | 20.47% | $11.3B | $11.9B |
| Q2 2024 | Jul 26, 2024 | $1.62 | $2.07 | 27.81% | $11.5B | $12.2B |
| Q1 2024 | Apr 25, 2024 | −$4.41 | −$4.40 | 0.28% | $11.5B | $11.9B |
| Q4 2023 | Feb 2, 2024 | $1.55 | $1.70 | 9.42% | $11.2B | $11.5B |
| Q3 2023 | Oct 26, 2023 | $1.76 | $2.00 | 13.37% | $11.0B | $11.0B |
| Q2 2023 | Jul 27, 2023 | $1.96 | $1.75 | -10.79% | $11.8B | $11.2B |
| Q1 2023 | Apr 27, 2023 | $1.97 | $2.05 | 3.95% | $11.5B | $11.3B |
| Q4 2022 | Feb 2, 2023 | $1.73 | $1.82 | 5.41% | $11.2B | $11.4B |
| Q3 2022 | Oct 26, 2022 | $1.83 | $1.99 | 8.85% | $11.1B | $11.2B |
| Q2 2022 | Jul 27, 2022 | $1.77 | $1.93 | 8.99% | $11.4B | $11.9B |
| Q1 2022 | Apr 29, 2022 | $1.91 | $1.96 | 2.39% | $11.4B | $11.6B |
| Q4 2021 | Feb 4, 2022 | $1.80 | $1.83 | 1.88% | $12.0B | $12.0B |
| Q3 2021 | Oct 27, 2021 | $1.92 | $2.00 | 4.24% | $11.6B | $11.6B |

## Frequently Asked Questions

### When did Bristol-Myers Squibb (BMY) last report earnings?

Bristol-Myers Squibb last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did BMY beat earnings estimates?

Yes. Bristol-Myers Squibb reported EPS of $2.04 for Q2 2026 against a $1.60 estimate — a 27.73% beat.

### How much revenue did BMY report last quarter?

Bristol-Myers Squibb reported $13.0B in revenue for Q2 2026, against a consensus estimate of $11.7B.

## Similar Stocks

- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [EXEL](https://www.lighthorse.io/tickers/exel) — Exelixis, Inc. - Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).